Hasan Rizvi
Barts Health NHS Trust
31 Papers
30 Citations
Hasan Rizvi is an academic researcher from Barts Health NHS Trust. The author has contributed to research in topics: Medicine & Tocilizumab. The author has an hindex of 10, co-authored 26 publications. Previous affiliations of Hasan Rizvi include Queen Mary University of London & University College London.
Chat about Author
Papers
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial
Frances Humby,Frances Humby,Patrick Durez,Patrick Durez,Maya H Buch,Maya H Buch,Myles Lewis,Myles Lewis,Hasan Rizvi,Hasan Rizvi,Felice Rivellese,Felice Rivellese,Alessandra Nerviani,Alessandra Nerviani,Giovanni Giorli,Arti Mahto,Carlomaurizio Montecucco,Bernard Lauwerys,Bernard Lauwerys,Nora Ng,Pauline Ho,Michele Bombardieri,Michele Bombardieri,Vasco C. Romão,Patrick Verschueren,Stephen Kelly,Pier Paolo Sainaghi,Nagui Gendi,Bhaskar Dasgupta,Alberto Cauli,Piero Reynolds,Juan D. Cañete,Robert J Moots,Peter C. Taylor,Christopher J Edwards,John D. Isaacs,John D. Isaacs,Peter Sasieni,Ernest Choy,Ernest Choy,Costantino Pitzalis,Costantino Pitzalis,Charlotte Thompson,Serena Bugatti,Mattia Bellan,Mattia Congia,Christopher Holroyd,Arthur G. Pratt,João Eurico Fonseca,Laura White,Louise Warren,Joanna Peel,Rebecca Hands,Liliane Fossati-Jimack,Gaye Hadfield,Georgina Thorborn,Julio A. Ramirez,Raquel Celis +57 more
TL;DR: In this paper, the effect of tocilizumab compared with rituximab in patients with rheumatoid arthritis who had an inadequate response to anti-tumour necrosis factor (TNF) stratified for synovial B-cell status.
222
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
Anna Elisa Andrea Surace,Katriona Goldmann,Elisabetta Sciacca,Cankut Çubuk,Giovanni Giorli,Christopher Jones,Liliane Fossati-Jimack,Georgina Thorborn,Manzoor Ahmed,Edoardo Prediletto,Sarah E. Church,Brian Hudson,Sarah Warren,Paul M. McKeigue,Frances Humby,Michele Bombardieri,Michael R. Barnes,Costantino Pitzalis,Felice Rivellese,Alessandra Nerviani,Myles Lewis,Patrick Durez,Maya H Buch,Hasan Rizvi,Arti Mahto,Carlomaurizio Montecucco,Bernard Lauwerys,Nora Ng,Pauline Ho,Vasco C. Romão,João Eurico Fonseca,Patrick Verschueren,Stephen Kelly,Pier Paolo Sainaghi,Nagui Gendi,Bhaskar Dasgupta,Alberto Cauli,Piero Reynolds,Juan D. Cañete,Julio Ramirez,Raquel Celis,Robert J. Moots,Peter C. Taylor,Christopher Edwards,John T. Isaacs,Peter Sasieni,Ernest Choy,Charlotte Thompson,Serena Bugatti,Mattia Bellan,Mattia Congia,Christopher Holroyd,Arthur G. Pratt,Laura White,Louise Warren,Joanna Peel,Rebecca Hands,Gaye Hadfield +57 more
TL;DR: In this article , in-depth histological/molecular analyses of R4RA synovial biopsies identify humoral immune response gene signatures associated with response to rituximab and tocilizumab, and a stromal/fibroblast signature in patients refractory to all medications.
B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure
Felice Rivellese,Frances Humby,Serena Bugatti,Liliane Fossati-Jimack,Hasan Rizvi,Davide Lucchesi,Gloria Lliso-Ribera,Alessandra Nerviani,Rebecca Hands,Giovanni Giorli,Barbara Frias,Georgina Thorborn,Edyta Jaworska,Christopher R. John,Katriona Goldmann,Myles Lewis,Antonio Manzo,Michele Bombardieri,Costantino Pitzalis,Peac-R Ra Investigators +19 more
TL;DR: The relationship of synovial B cells to clinical phenotypes at different stages of disease evolution and drug exposure in rheumatoid arthritis (RA) is defined.
46
BRAF V600E mutation‐specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia
Ayse U. Akarca,Vishvesh H. Shende,Alan D. Ramsay,Tim C. Diss,Maria Pane-Foix,Hasan Rizvi,Maria Calaminici,Thomas M. Grogan,David C. Linch,Teresa Marafioti,Teresa Marafioti +10 more
TL;DR: This dissertation aims to provide a history of bone marrow transplantation in France and its role in the treatment of cancer from 1989 to 2002.
40
Novel markers in pediatric-type follicular lymphoma.
Claudio Agostinelli,Ayse U. Akarca,Alan G. Ramsay,Hasan Rizvi,Manuel Rodriguez-Justo,Manuel Rodriguez-Justo,Sabine Pomplun,Ian Proctor,Elena Sabattini,David C. Linch,Stephen Daw,Stefania Pittaluga,Stefano Pileri,Elaine S. Jaffe,Leticia Quintanilla-Martinez,Teresa Marafioti,Teresa Marafioti +16 more
TL;DR: The study confirmed the unique morphological and immunophenotypic features ofPTFL and suggests that FOXP-1 can represent a novel useful diagnostic marker in the differential diagnosis between PTFL and FH.